A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: A pilot study

Alternative Therapies in Health and Medicine

Volumn 20, Issue 5, 2014, Pages 18-23

  Hobbs, Thomas ^a   Caso, Richard ^b   McMahon, David ^c   Nymark, Maria ^d  

^a Power Med   (United States)

^b Orange County Heart   (United States)

^c Aesthetics Inc   (United States)

^d BioButlers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CHOLESTEROL; CHOLESTIN; DRUG COMBINATION; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID;

ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PILOT STUDY; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FATTY ACIDS, OMEGA-3; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PILOT PROJECTS; UNITED STATES; YOUNG ADULT;

EID: 84925223619     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.
2. Golomb BA, Evans MA. Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373-418.
3. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.
4. Lowe G, Rumley A, Norrie J, et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost. 2000;84(4):553-558.
5. Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010;105(2):198-204.
6. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: A meta-analysis of randomized controlled trials. Chin Med. Nov 2006;1:4.
7. Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101(12):1689-1693.
8. Becker DJ, Gordon RY, Morris PB, et al. simvastatin vs therapeutic lifestyle changes and supplements: Randomized primary prevention trial. Mayo Clin Proc. 2008;83(7):758-764.
9. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999;69(2):231-236.
10. Lin CC, Li TC, Lai MM. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005;153(5):679-686.
11. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: A scientific statement from the Amer i can Heart Assoc iat ion. Circulation. 2011;123(20):2292–2333.
12. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomized open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-1098.
13. Gruppo Italiano per lo Studio della Sopravvivenza nelľInfarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet. 1999;354(9177):447-455.
14. Castano G, Fernandez L, Mas R, et al. Effects of addition of polycosanol to omega-3 fatty acid therapy on the lipd profile of patients with type II hypercholesterolaemia. Drugs R D. 2005;6(4):207-219.
15. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice productsbuyer beware! Arch Intern Med. 2010; 70(19):1722-1727.
16. University of Maryland Medical Center. Red yeast rice. http://umm.edu/health/medical/altmed/supplement/redyeast-rice#ixzz30CZPFZcf. Updated June 24, 2013. Accessed April 28, 2014.
17. Fish Oil Safety. www.fishoilsafety.com. Accessed May 2, 2014.
18. Huang J, Frohlich J, Ignaszewski AP. The impact of dietary changes and dietary supplements on lipid profile. Can J Cardiol. 2011;27(4):488-505.
19. US Environmental Protection Agency. Polychlorinated biphenyls (PCBs). http://www.epa.gov/epawaste/hazard/tsd/pcbs/about.htm. Updated April 8, 2013. Accessed May 19, 2014.
20. Davignon J. Cardioprotective and other emerging effects of statins. Int J Clin Pract Suppl. October 2004;(143):49-57.